Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 13Active not recruiting 10Completed 7Terminated 5Unknown 3Withdrawn 2Not yet recruiting 2

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Melanoma 3Neoplasms 1Neoplasm Metastasis 1

Interventions

Cisplatin 352Oxaliplatin 262Capecitabine 258Radiotherapy 240Gemcitabine 223Docetaxel 223Carboplatin 223Cyclophosphamide 219Drug Therapy 218Paclitaxel 205apatinib 201Bevacizumab 195camrelizumab 190Fluorouracil 187sintilimab 133Blood Specimen Collection 125Irinotecan 124Dexamethasone 123Etoposide 119Radiosurgery 118toripalimab 117Surgical Procedures, Operative 115pembrolizumab 110Pemetrexed 108anlotinib 105S 1 (combination) 105Surveys and Questionnaires 101Leucovorin 101Nivolumab 98tislelizumab 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × OTHER × encorafenib × Clear all
NCT04720768 2024-01-05

CELEBRATE

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Unknown
78 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT05767879 2023-03-14

(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

Leiden University Medical Center

Phase 2 Unknown
28 enrolled
Dermatologic

Melanoma

NCT05097378 2021-10-28

PREMIUM

Cambridge University Hospitals NHS Foundation Trust

Phase 2 Unknown
45 enrolled
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡